Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ONO-7913-04: ONO-7913 Phase 1 Study

ABSTRACT: Interventions: Administration of ONO-7913 and ONO-4538 with FOLFOX and Bevacizumab or Cetuximab Primary outcome(s): Tolerability, safety Study Design: non-randomized controlled trial, open(masking not used), uncontrolled control, single assignment, treatment purpose

DISEASE(S): Unresectable Advanced Or Recurrent Colorectal Cancer

PROVIDER: 2613449 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

ONO-4578-02:ONO-4578 Phase 1 Study

Project description:Interventions: ONO-4578 given as combinations of ONO-4578, ONO-4538, XELOX and Bevacizumab Primary outcome(s): Safety, tolerability Study Design: non-randomized controlled trial, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2613172 | ecrin-mdr-crc

Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Project description:The objective of the study is to evaluate the safety, tolerability, pharmacokinetics, efficacy and biomarker of ONO-4578 and combinations of ONO-4578 and ONO-4538 in subjects with advanced or metastatic solid tumors and subjects with unresectable, advanced or recurrent gastric cancer, unresectable, advanced or recurrent colorectal cancer.

| 2244525 | ecrin-mdr-crc

ONO-4538/CA2099X8 Phase 2/3 Study(ONO-4538-72/CA2099X8)

Project description:Intervention name : ONO-4538/BMS-936558 INN of the intervention : Nivolumab Dosage And administration of the intervention : Intravenous administration Control intervention name : Fluorouracil, Leucovorin Calcium Folinate, Oxaliplatin, Bevacizumab INN of the control intervention : Fluorouracil, Leucovorin Calcium Folinate, Oxaliplatin, Bevacizumab Dosage And administration of the control intervention : Intravenous administration Primary outcome(s): efficacy PFS Study Design: Randomized, open-label

| 2658327 | ecrin-mdr-crc

ONO-4538/CA2099X8 Phase 2/3 Study(ONO-4538-72/CA2099X8)

Project description:Interventions: investigational material(s) Generic name etc : ONO-4538/BMS-936558 INN of investigational material : Nivolumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Intravenous administration control material(s) Generic name etc : Fluorouracil, Leucovorin Calcium Folinate, Oxaliplatin, Bevacizumab INN of investigational material : Fluorouracil, Leucovorin Calcium Folinate, Oxaliplatin, Bevacizumab Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : Intravenous administration Primary outcome(s): efficacy PFS Study Design: Randomized, open-label

| 102159 | ecrin-mdr-crc

Identification of SNP candidates associated with chemo-responsiveness in colorectal cancer patients

Project description:Response rates of 118 colorectal cancer patients to regiments were evaluated by histoculture drug response assay. Affymetrix SNP 6.0 chips were used to determine genotypes of the same colorectal cancer patients. SNPs associated with chemosensitivity to treatment regiments were identified by genome-wide association study. AV: avastin (Bevacizumab), ER: Erbitux (Cetuximab), FXA: bevacizumab + FOLFOX, FXE: Cetuximab + FOLFOX , FRA: Bevacizumab + FOLFIRI, FRE: Cetuximab + FOLFIRI; Numbers (0-100) represent responsiveness to the given drug regimens; the larger, the better responsive to given regimens

2011-03-25 | GSE21228 | GEO

Synthetic prostacyclin ONO-1301 Enhance Survival of Human Pluripotent Stem Cell-Derived Cardiomyocytes Tissue Transplantation in a Rat Myocardial Infarction Model

Project description:To investigate whether ONO-1301 activates angiogenesis-related signaling pathways in 253G1 derived cardiomyocytes

2023-03-26 | GSE205622 | GEO

Proteomic characterization of the colorectal cancer response to chemoradiation and targeted therapies

Project description:Herein, we assembled a cohort composed of 254 CRC patients, including discovery cohort (N = 124) and validation cohort (N = 130), which received either chemotherapy (mainly FOLFOX therapy), chemoradiotherapy (mainly FOLFOX combined with radiotherapy), or targeted combination therapy (mainly FOLFOX combined with cetuximab).

2023-10-30 | PXD046566 |

OGSG2101:Efficacy and Safety of BEACON triplet regimen for early relapse BRAF-mutated colorectal cancer

Project description:Interventions: Encorafenib,binimetinib,cetuximab Primary outcome(s): Objective response rate Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2615453 | ecrin-mdr-crc

The feasibility study of FOLFOX therapy in gastrointestinal cancer patients undergoing hemodialysis

Project description:Interventions: FOLFOX therapy;Antineoplastic Combined Chemotherapy Protocols Primary outcome(s): Part1 : Recommended starting dose Part2: Completion rate of chemotherapy Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2615374 | ecrin-mdr-crc

Switch Maintenance Study

Project description:Interventions: CapeOX+Bev ;Capecitabine1000mg/m2 oral administration twice a day Day1-15+Oxaliplatin130mg/m2 120minute DIV+Bevacizumab5.0 mg/kg given on day 1,15 FOLFOX+Bev;Oxaliplatin85mg/m2 120minute DIV+LEVOFOLINATE200mg/m2 120minute DIV+Fluorouracil400mg/m2 rapid DIV+Fluorouracil2400mg/m2 46minute DIV+Bevacizumab DIV5.0 mg/kg Day1,15 TAS-102+Bev;TAS-102 35 mg/m2/time,oral administration twice a day Day1-5, TAS-102 oral administration twice a day Day8-12+Bevacizumab DIV5.0 mg/kg Day1,15 Primary outcome(s): Progression free survival Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2612965 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data